Search

Emricasan

It is developed by Pfizer and made in such a way that it protects liver cells from excessive apoptosis. … Emricasan is the first caspase inhibitor tested in human which has received orphan drug status by FDA.

Podofilox

A lignan found in podophyllin resin from the roots of podophyllum plants. It is a potent spindle poison, toxic if taken internally, and has been used as a cathartic. … It is very irritating to skin and mucous membranes, has keratolytic actions, has been used to treat warts and keratoses, and may have antineoplastic properties, as do some of its congeners and derivatives

Dapsone

It is also used with pyrimethamine in the treatment of malaria. (From Martindale, The Extra Pharmacopoeia, 30th ed, p157-8) … Its mechanism of action is probably similar to that of the sulfonamides which involves inhibition of folic acid synthesis in susceptible organisms.

Cilomilast

Following four clinical trials, the drug proved to be effective in treating COPD, however it has never been marketed due to a poor side effect profile. … It is orally active and acts as a selective Phosphodiesterase-4 inhibitor.

Cortisone acetate

Cortisone acetate was first isolate in 1935 and became more widely researched in 1949. … [A226300,L13203] Cortisone acetate was granted FDA approval on 13 June 1950.[L15107]

Chromium gluconate

Chromium nicotinate

2,4-Dinitrophenol

A toxic dye, chemically related to trinitrophenol (picric acid), used in biochemical studies of oxidative processes where it uncouples oxidative phosphorylation. … It is also used as a metabolic stimulant. (Stedman, 26th ed)

LM-609

In addition to cancer, the protein has been implicated in bone destruction in rheumatoid arthritis and the inflammatory process in psoriasis. … LM-609 (Vitaxin) is an artificial antibody that targets a protein on the surface of newly forming blood vessels, as well as on certain tumors.

Rindopepimut

The US FDA granted it Breakthrough Therapy Designation for glioblastoma in Feb 2015. … Rindopepimut (CDX-110) is an injectable peptide cancer vaccine which targets a mutant protein called EGFRvIII present in about 25% to 30% of glioblastoma cases.